Trending Now
Markets bounce back post early shakeup
Markets recovered nicely off what looked like a down day. It’s not that surprising since we closed last week at the highs....
BrideBio Pharma Inc. (NASDAQ:BBIO) Announces Its Q3 2020 Financial Results And...
BrideBio Pharma Inc. (NASDAQ:BBIO) has announced its Q3 2020 financial results and provided business highlights on its operations for the period.
BridgeBio to merge with...
Denali Therapeutics Inc. (NASDAQ:DNLI) Announces Q3 2020 Financial Results And Collaboration...
Denali Therapeutics Inc. (NASDAQ:DNLI) has announced its Q3 2020 financial results and offered business highlights for the quarter ended September 30, 2020.
Denali realized $9.4...
Popular News
FDA Accepts Ardelyx Inc.’s (NASDAQ:ARDX) NDA Filing For Tenapanor in Controlling...
Ardelyx Inc. (NASDAQ:ARDX) has announced that the US FDA has accepted its NDA filing for tenapanor for controlling serum phosphorous in chronic kidney disease...
MAKE IT MODERN
LATEST REVIEWS
Netflix Inc (NASDAQ:NFLX) reacts poorly to earning
Netflix Inc (NASDAQ:NFLX) announced its earnings yesterday, and the stock reacted quite poorly. So, we have the makings for a nice bearish...
MAKE IT MODERN
PERFORMANCE TRAINING
Nabriva’s (NASDAQ:NBRV) XELENTA Shows Efficacy In Treating Community-Acquired Bacterial Pneumonia Patients Above 65 Years
Nabriva Therapeutics plc (NASDAQ:NBRV) has announced that XELENTA (lefamulin ) has shown significant efficacy in a posthoc analysis of LEAP 1and LEAP Phase 3...
Aquestive Therapeutics Inc. (NASDAQ:AQST) Reports Revenue Of $8.3 Million In Q3 2020 Boosted By...
Aquestive Therapeutics Inc. (NASDAQ:AQST) has announced its Q3 2020 financial results and provided recent business development updates.
Aquestive posts revenue of $8.3 million
The company reported...
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) Releases Encouraging Provisional Data From AROAAT2002 Study Evaluating ARO-AAT
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) has announced positive provisional results of the 24-week liver biopsy AROAAT2002 open-label second phase clinical trial of ARO-ATT. ARO-ATT is...
Market pull back, can you take it seriously ?
Yesterday's market action was tepid. We’re still treading water on extremely light volume with little to see. Most of the action has...
Cardiff Oncology (NASDAQ:CRDF) Reports Its Q3 2020 Financial Results And Onvansertib Development Updates
Cardiff Oncology (NASDAQ:CRDF) has announced its financial results and business highlights for the three months ended September 30, 2020.
Cardiff presents onvansertib data on KRAS-mCRC
Dr...
MAKE IT MODERN
POPULAR
[/tdc_zone]